6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

• Status: Terminated
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Duloxetine Hydrochloride

Criteria

Inclusion Criteria:

• Provision of signed, written, and dated Informed Consent

• Documented primary clinical diagnosis of Major Depressive Disorder

Exclusion Criteria:

• Patients with a secondary psychiatric disorder including bipolar disorder, psychotic disorders (i.e. schizophrenia, schizoaffective disorder, depression with psychotic features), GAD and social anxiety disorder

• Patients whose current episode of depression started less than 4 weeks before enrollment

• History of inadequate response of antidepressants during current depressive episode